Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Salud, A.
Escudero, P.
Feliu, J.
Lopez-Gomez, L.
Bolanos, M.
Galan, A.
Yubero, A.
Vicent, J. M.
Losa, F.
Gonzalez-Baron, M.
机构：
[1] Hosp Arnau Vilanova, Med Oncol Serv, Lleida, Spain
[2] Hosp Lozano Blesa, Med Oncol Serv, Zaragoza, Spain
[3] Hosp La Paz, Med Oncol Serv, Madrid, Spain
[4] Hosp Virgen Salud, Med Oncol Serv, Toledo, Spain
[5] Hosp San Pedro Alcantara, Med Oncol Serv, Caceres, Spain
[6] Hosp Sagunto, Med Oncol Serv, Valencia, Spain
[7] Hosp Obispo Polanco, Med Oncol Serv, Teruel, Spain
[8] Hosp Gen Univ, Med Oncol Serv, Valencia, Spain
[9] Hosp Creu Roja De Barcelona, Med Oncol Serv, Barcelona, Spain
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [21] A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (PTS) with advanced or metastatic colorectal cancer (MCRC)
    Maroun, Jean A.
    Jonker, Derek
    Goel, Rakesh
    Cripps, Christine
    Lister, Diane
    Chiritescu, Gabriela
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [22] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    British Journal of Cancer, 2010, 102 : 1468 - 1473
  • [23] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Safont, M. J.
    Salud, A.
    Losa, F.
    Garcia-Giron, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Madronal, C.
    Bolanos, M.
    Gil, M.
    Llombart, A.
    Castro-Carpeno, J.
    Gonzalez-Baron, M.
    BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1468 - 1473
  • [24] Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
    Cupini, S.
    Bursi, S.
    Masi, G.
    Loupakis, F.
    Barbara, C.
    Barletta, M. T.
    Baldi, G. G.
    Vasile, E.
    Fornaro, L.
    Petrini, I.
    Allegrini, G.
    Antonuzzo, A.
    Di Marsico, R.
    Andreuccetti, M.
    Ricci, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [25] PRELIMINARY EFFICACY, SAFETY AND OPERABILITY OF BEVACIZUMAB(BV) PLUS CAPECITABINE PLUS OXALIPLATIN (XELOX) AS FIRST-LINE THERAPY IN JAPANESE PATIENTS (PTS) WITH INITIALLY UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC)
    Yamaguchi, K.
    Boku, N.
    Kato, K.
    Komatsu, Y.
    Muro, K.
    Hamamoto, Y.
    Sato, A.
    Koizumi, W.
    Mizunuma, N.
    Takiuchi, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [26] CAPECITABINE AND OXALIPLATIN (XELOX) COMBINATION CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER-A PHASE II STUDY
    Tawfik, Hesham
    El-Deen, Hanan Gamal
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 98
  • [27] Phase II study of biweekly XELOX (capecitabine and oxaliplatin) as first line chemotherapy in elderly patients with metastatic colorectal cancer
    Grande, C., Sr.
    Quintero, G.
    Mel, J. R.
    Huidobro, G.
    Campos, B.
    Candamio, S.
    Mendez, J. C.
    Salgado, M.
    Alvarez, E.
    Casal, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
    Yeon Hee Park
    Jae-Lyun Lee
    Baek-Yeol Ryoo
    Min-Hee Ryu
    Sung Hyun Yang
    Bong Seog Kim
    Dong Bok Shin
    Heung Moon Chang
    Tae Won Kim
    Young Jin Yuh
    Yoon-Koo Kang
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 623 - 629
  • [29] Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
    Park, Yeon Hee
    Lee, Jae-Lyun
    Ryoo, Baek-Yeol
    Ryu, Min-Hee
    Yang, Sung Hyun
    Kim, Bong Seog
    Shin, Dong Bok
    Chang, Heung Moon
    Kim, Tae Won
    Yuh, Young Jin
    Kang, Yoon-Koo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (04) : 623 - 629
  • [30] Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
    Cassinello, J.
    Alvarez, J. V.
    Garcia-Lopez, M. J.
    Pujol, E.
    Colmenarejo, A.
    De Segovia, F.
    Marcos, F.
    Filipovich, E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 200
12345